Stock_Titan Posted - 6 hours ago

$JAZZ Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 https://www.stocktitan.net/news/JAZZ/jazz-pharmaceuticals-to-present-data-across-growing-oncology-vzl4mfxxxj21.html

GPS_OS_21_vs_SOC_5 Posted - 1 day ago

$SLS Pennies Nickels and Dimes will be Irrelevant when SLS starts Jumping in Whole Dollars.... P3 Results Imminent. - What is an immunotherapy that will treat 25,000 aml remission patients worth? - Compare whatever you think that is worth to the current manipulated 90m market value. - $cpxx was a $50m mcap when it released its AML p3 data. It was a $750M mcap 3 weeks later, and then got bought 60 days after that for $1.5B $jazz Something very similar is about to happen here.

forprofit12 Posted - 1 day ago

$JAZZ but before or after ER?

Fred_G_Sanford Posted - 1 day ago

@LarryYMB That’s exactly right! And the courts will show no mercy to the scoundrels running $JAZZ who have clearly conspired to keep a vastly superior product off the market!!

Kloompa Posted - 2 days ago

$JAZZ They are forecasting just a hair over $1B per quarter in revenue this year ($4B to $4.2B for 2024). But the earnings whisper projections and analysts are saying something like $850M to $970M in revenue this first quarter 2024. So earnings surprise to the downside? Or is JAZZ being led by dingbats who would set themselves up for an epic fail with over projection on their numbers? Or are they planning to make up for the revenue numbers in later quarters? Inquiring minds would like to know. Seems like a miss on this report would send them down to $90-100 range and a beat would send them back to $120-130 range.

HScottMatusow Posted - 2 days ago

GlycoMimetics: $GLYC A Potential Game Changer In Blood Cancers With Near-Term Catalysts https://talkmarkets.com/content/stocks--equities/glycomimetics-a-potential-game-changer-in-blood-cancers-with-near-term-catalysts?post=437691&userid=5651 $ABBV $NVS $JAZZ $XBI #Pharma #Biotech

Stock_Titan Posted - 1 week ago

$JAZZ Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 https://www.stocktitan.net/news/JAZZ/jazz-pharmaceuticals-to-report-2024-first-quarter-financial-results-wnshwufajzad.html

Kloompa Posted - 1 week ago

$JAZZ All depends on how they perform with relation to forecast. Report coming in approximately 2.5 weeks.

LarryYMB Posted - 1 week ago

$JAZZ wait for Q2, will get worse, wondering when my boy Jason from BofA going to get re-assigned or let go...

Kloompa Posted - 1 week ago

$JAZZ

Magic8BallResponse Posted - 1 week ago

$JAZZ Wow..... not pretty..... Mark your calendars..... 1/1/26

Iwillplay Posted - 1 week ago

$JAZZ 52 week low. Way to go.

Magic8BallResponse Posted - 1 week ago

$JAZZ Generic xyrem on the horizon. Company should consider options to exit oxy franchise.

Magic8BallResponse Posted - 1 week ago

$JAZZ Maybe the company should consider splitting up oncology from neuro. I imagine it's hard to focus on both at some level.

Magic8BallResponse Posted - 1 week ago

$JAZZ HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST

Magic8BallResponse Posted - 1 week ago

$JAZZ After eight weeks, patients treated with TAK-861 saw significantly better outcomes in the Maintenance of Wakefulness Test—the trial’s primary endpoint—with a p-value of less than 0.001, according to Takeda. TAK-861 also outperformed placebo in terms of key secondary endpoints, including the Epworth Sleepiness Scale and Weekly Cataplexy Rate.

Magic8BallResponse Posted - 1 week ago

$JAZZ Alkermes plc announced positive results from a phase 1b study evaluating ALKS 2680, an oral orexin 2 receptor agonist, for treating narcolepsy type 2 and idiopathic hypersomnia. The study showed statistically significant improvements in wakefulness and sleep latency compared to placebo across various doses. ALKS 2680 was well tolerated, with most adverse events being mild and transient. These results support further clinical trials, highlighting its potential as a new treatment for sleep disorders. Plans for a phase 2 study are underway.

Magic8BallResponse Posted - 1 week ago

$JAZZ A few unknowns. When does AG Xyrem end? What will be the outcome of Xyrem antitrust. If generic pricing (non AG) begins to eat into non generics its going to get interesting. Not to mention orexins on the horizon.

Steve_TheBull_Rogers Posted - 1 week ago

@sem__sem Yeah I have a friend that sold $JAZZ at 8 from a 4 avg back in the day, went over 180s People are so stuck in their perception of how much a large bio will pay for a small bio they leave so much money behind when it happens Sad really

pgod Posted - 1 week ago

$JAZZ why the Jump AH?

Jwa68 Posted - 1 week ago

$GANX Ironically, our new CFO Gene Mack was the sole analyst covering $JAZZ when it was at just $2. More I learn about him, the more impressed I am and confident in the future. He is everything the last CFO was not. He's a former analyst who is well regarded with an extensive network of institutional relationships and importantly, he knows the capital markets well. I think it a short matter of time before his influence, along with Jonas, the new CMO, begins to pay dividends. Lots to be said and perceived when two guys like this join a management team during an active clinic trial and take their own compensation upside in options and not traditional RSU's. They only win of we win and that's the way it should be.

Kloompa Posted - 1 week ago

@NLST12345 How could it be deemed as manipulated when people leave on their own volition after a binary event? Once invalidated, they will leave and move on. That's not manipulation. That's called taking your losses. Holding the stock forever is missed opportunity cost. You want a good stock that is overweight right now? Buy $JAZZ at any price under $120.

erevnon Posted - 2 weeks ago

Cantor Fitzgerald reiterates Jazz Pharmaceuticals $JAZZ at Overweight and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

Will2ride1 Posted - 2 weeks ago

$JAZZ good for a swing 📈

Stock_Titan Posted - 2 weeks ago

$JAZZ Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting https://www.stocktitan.net/news/JAZZ/jazz-pharmaceuticals-to-showcase-expansive-neuroscience-portfolio-at-yz4l8c7d32fu.html

GakiYoui_Atsu Posted - 2 weeks ago

$AEVA Aeva Technologies, Inc. (NYSE:AEVA) Receives $2.29 Average Target Price from Analysts $JAZZ Analysts Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Target Price at $190.70 $LNC Brokerages Set Lincoln National Co. (NYSE:LNC) Target Price at $26.20 $CYRX Needham & Company LLC Trims Cryoport (NASDAQ:CYRX) Target Price to $18.00 $WIMI Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud(NASDAQ: WIMI)

LarryYMB Posted - 2 weeks ago

$JAZZ dang still above hundred dolla, wait for new ER, 99

GPS_OS_21_vs_SOC_5 Posted - 2 weeks ago

$SLS We are going to see several days with +100% share price increases. - this $75m mcap is by all metrics worth 100X more +’when the Imminent Phase 3 results are announced. - Celator was a $50M mcap the day it released its P3 aml trial results, it was a $750M mcap 3 weeks later, then got bought by $jazz for $1.6B, 6 weeks after that. - something very similar will be happening here. Imminently. imp note, Gps Immunotherapy will treat 5x the number of patients $cpxx's drug does. - even the "secondary" SLS asset, 009 has a market comp, $KURA , at the same stage of P2 development worth $1.6B - DD $XBI $VINC

Kloompa Posted - 2 weeks ago

$JAZZ How low will she go?

Johnmtnb2018 Posted - 2 weeks ago

$JAZZ $KURA $SLS Imminent 🙌💎🙌